Boonnak, K., Vogel, L., Orandle, M., Zimmerman, D., Talor, E., and Subbarao, K. (2013). Antigen-activated dendritic cells ameliorate influenza A infections. Journal of Clinical Investigation .123(7): 2850-2861. (Link to article)
K. Rosenthal. “LEAPS Technology Vaccine Promotes T cell Responses to Prevent and Treat Ongoing HER-2/neu Tumors in a Mouse Model of Breast Cancer.” Presented at the GTCbio 11th Annual Vaccines All Things Considered, Boston, MA. July 9 2013.
D. Zimmerman. “LEAPS peptide vaccination alters T cell phenotype and suppresses joint inflammation in a murine model of rheumatoid arthritis.” Presented at the AAI annual meeting, Honolulu, HI, May 6 2013.
Rosenthal, K. S., Taylor, P., and Zimmerman, D. H. (2012). J-LEAPS peptide and LEAPS dendritic cell vaccines. Microbial biotechnology 5, 203-213. (Link to abstract)
Zimmerman, D. H., Steiner, H., Carambula, R., Talor, E., and Rosenthal, K. S. (2012). LEAPS Therapeutic Vaccines as Antigen Specific Suppressors of Inflammation in Infectious and Autoimmune Diseases. Journal of Vaccines & Vaccination 03. (Link to article)
D. Zimmerman. “CEL-2000 Forward by Producing a Product Suitable as a Therapeutic Rheumatoid Arthritis (RA) Vaccine.” Presented at the GTCbio 8th Annual Vaccines all Things Considered Conference. Washington D.C. November 8, 2010.
K. Rosenthal. “LEAPS Peptide and LEAPS-Dendritic Cell Vaccines Act as Adjuvant and Immunogen to Prevent Infection and Treat Disease.” Poster at Cancer Vaccine Conference. Boston MA. June 28 2010.
P. Taylor. “J-LEAPS Vaccines Mature Mouse Bone Marrow Cells to Dendritic Cells-1 (DC1) which can Deliver Protective Immunity.” Presented at the Federation of Clinical Immunology Societies (FOCIS). Boston, MA. June 27 2010.
Taylor, P., G. Koski, C. Paustian, P. Cohen, F. Moore, D. Zimmerman, and K. Rosenthal. J-L.E.A.P.S.™ Vaccines Initiate Murine Th1 Responses By Activating Dendritic Cells. Vaccine. August 2010, 28:5533-42. (Link to abstract)
Taylor, P., C. Paustian, G. Koski, D. Zimmerman, and K. Rosenthal. Maturation of dendritic cell precursors into IL12 producing DCs by J-LEAPS. Cellular Immunology. 2010, 262:1-5 (Link to abstract)
Zimmerman D., P. Taylor, A. Bendele, R. Carambula, Y. Duzant, S. O’Neill, E. Talor, K. Rosenthal. CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease Development and Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen Type II Induced arthritis in the DBA Mouse Model. Int Immunopharmacol. April 2010, 10:412-421. (Link to abstract)
D. Zimmerman. “A L.E.A.P.S.™ Therapeutic vaccine for Rheumatoid Arthritis.” Presented at the GTCbio 7th Annual Vaccines all Things Considered Conference. Washington D.C. November 10, 2009.
D. Zimmerman. “CEL-2000 Therapeutic Vaccine Arrests Disease Progression in the Collagen Type II (Bovine) Murine Model for Rheumatoid Arthritis by Altering Cytokine Environment.”Poster at the American College Rheumatology meeting. Philadelphia, PA. October 12, 2009.
K. Borthakur. “Ex Vivo Restimulation Assay for T-cell Responses for Tuberculosis using LEAPS-Peptide Heteroconjugates.” Poster at the American Society of Microbiology. Philadelphia, PA. May 12, 2009.
K. Rosenthal. “The J-L.E.A.P.S.™ immunogens direct the immune response by promoting development of human immature dendritic cells into IL-12 producing dendritic cells (DC1s).” Presented at the National Foundation of Infectious Diseases meeting. Baltimore, MD. April 27, 2009.
P. Taylor. “Immunization with a L.E.A.P.S.™ Heteroconjugate Containing the J Peptide from Beta-2 Microglobulin Elicits a T helper 1 Cytokine Response.” Poster at the Federation of Clinical Immunology Societies (FOCIS) meeting. Boston, MA. June 27, 2008.
Cihakova, D., J. Barin, M. Kimura, G. Baldeviano, M. Talor, D. Zimmerman, E. Talor, and N. Rose. L.E.A.P.S.™ Heteroconjugate is able to Prevent and Treat Experimental Autoimmune Myocarditis by Altering Trafficking of Autoaggressive Cells to the Heart. Int Immunopharmacol. May 2008, 8:624-633. (Link to paper)
D. Zimmerman. “Preclinical Development of Vaccines: with Examples of L.E.A.P.S.(TM) Therapeutic Vaccines for Arthritis and Experimental Autoimmune Myocarditis.” Presented at Marcus Evans Conference on Immunogenicity. Amsterdam, Netherlands. September 5, 2008.
D. Zimmerman. “A L.E.A.P.S.™ Therapeutic Vaccine for Rheumatoid Arthritis.” Presented at SMi’s 4th Biannual Vaccine Conference. London, England. June 17, 2008.
D. Zimmerman. “Enhanced immunogenicity of avian influenza antigen H5 by addition of CEL-1000 to MAS-1.” Presented at the American Society of Microbiologists 107th annual general meeting. Toronto, Canada. May 25, 2007.
E. Talor. “Long Term Cancer Survival Data with Multikine®.” Presented at the First International Congress of the International Association of Oral Oncology. Amsterdam, the Netherlands. May 20, 2007.
D. Zimmerman. “Enhanced Immunogenicity of Recombinant HBV antigen by addition of CEL-1000 to MAS-1.” Presented at the 10th Annual Conference of the National Foundation for Infectious Diseases. Baltimore, MD. April 30, 2007.
D. Zimmerman, E. Talor and K. Rosenthal. “The Vaccine Conundrum.” The Scientist. April 2007. http://www.the-scientist.com
D. Zimmerman. “Immunopeptides as Therapeutics.” Presented at the GTCbio’s 4th Annual International Conference on Vaccines: All Things Considered. Arlington, VA. November 3, 2006.
D. Zimmerman. “Whither Peptide Vaccines.” Presented at the CHI Vaccine Conference. August 21-23, 2006.
E. Talor. “Long Term Survival Data with its Anti-Cancer Drug Multikine®.” Presented at the Vaccine Discovery and Commercialization. Philadelphia, PA. May 2006.
D. Zimmerman. “Immunopeptides as Therapeutic.” SMi Conference “Vaccines – From Bench to Bedside.“ May 22, 2006.
Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, Remenar E, Godeny M, Kasler M, Bencsik B, Repassy G, Szabo G, Velich N, Suba Z, Elo J, Balatoni Z, Pocza K, Zemplen B, Chretien P, Talor E. “Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.” Journal of Clinical Oncology. 2005 May 20; 23(15):3421-32.
N. Goel, D. Zimmermen and K. Rosenthal. “Ligand Epitope Antigen Presentation System Vaccines Against Herpes Simplex Virus.” Frontiers in Bioscience, January 2005; 10:966-974.
D. Zimmerman and K. Rosenthal. “The L.E.A.P.S.™ approach to vaccine development.”Frontiers in Bioscience, January 2005; 10:790-798.
D. Zimmerman. “Use of peptides to direct innate and adaptive immune Th1 responses.” Presented at the GTCBIO Conference: Vaccines All Things Considered. December 2, 2004.
N. Goel, D. Zimmerman and K. Rosenthal. “CEL-1000 activation of CD4 expressing mouse and human cells elicits Th1 directing cytokines and chemokines.” Presented at the 12thInternational Congress of Immunology, Toronto, Canada; July 2004.
Y. Charoenvit, G.T. Brice, D. Bacon, V. Majam, J. Williams, E. Abot, H. Ganesham, M. Sedegah, D.J. Carucci, D.H. Zimmerman. “A small peptide derived from human MHC ß2 chain induces complete protection against malaria in an antigen-independent manner.” Antimicrobial Agents and Chemotherapy, July 2004; 48(7):2455-63.
D. Zimmerman, N. Goel and K. Rosenthal. “Development of L.E.A.P.S.™ Vaccine for Herpes Simplex Virus.” Presented at the NIH SBIR Workshop. June 2004.
Y. Charoenvit, N. Goel, M. Whelan, K.S. Rosenthal, D.H. Zimmerman. “CEL-1000, a nineteen amino acid peptide with adjuvant activity for Th1 immune responses.” Vaccine, June 2004; 22(19):2368-73.
D. Zimmerman. “CEL-1000 prophylaxis in HSV and malaria murine models of human disease: The central role and timing of interferon gamma.” Presented at the GTCBIO Conference: Cytokines and Beyond. April 30, 2004.
J Timar, et al. “The Effect of Leukocyte Interleukin Injection (Multikine®) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer – A Multicenter Phase I/II Clinical Trial.” The Laryngoscope, December 2003; 113:2206-2217.
Y. Charoenvit, G.T. Brice, D. Bacon, V. Majam, J. Williams, E. Abot, H. Ganesham, M. Sedegah, D. Doolan, D.J. Carucci, D.H. Zimmerman. “A small peptide derived from human MHC ß2 chain induces complete protection against malaria in an antigen-independent manner.” Presented at the American Society of Tropic Medicine and Hygiene (ASTMH). November 2003.
N Goel, D Zimmerman, K Rosenthal. “A L.E.A.P.S.(TM) heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protections.” Vaccine, October 2003; 21:4410-4420.
K. Rosenthal, N. Goel, R. Singavarapu, D. Zimmerman. “CEL-1000 protects mice against HSV-1 challenge by stimulating IL-12 production.” Presented at ICAUC. September 14, 2003.
R Feinmesser, et al. “Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with Multikine®.” Arch Otolaryngology – Head & Neck Surgery, August 2003; 129: 874-881.
K Rosenthal, N Goel, D Zimmerman. “An immunolnodulating peptide (CEL-1000) elicits protection against HSV-1.” Presented at 16th International Conference on Antiviral Research. Savannah, GA, USA, April 2003.
D Zimmerman. “Peptide stimulated innate response and cytokines involved.” Presented at GTCBIO conference Cytokines and Beyond. San Diego, CA, USA, March 2003.
V Pisarev, P Parajuli, R Mosley, J Chavez, D Zimmerman, M Winship, J Talmadge. “Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine.” Vaccine 2002; 20:2358-2368.
N Goel, J Docherty, M Fu, D Zimmerman, K Rosenthal. “A modification of the epidermal scarification model of herpes simplex virus infection to achive a reproducible and uniform progression of disease.” J Virol Meth 2002; 106:153-158.
N Goel, H Mao, Q Rong, J Docherty, D Zimmerman, K Rosenthal. “The Ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential.” Arch Virol 2002; 147:763-773
Y Charoenvit, G Brice, V Majam, E Abot, H Ganeshan, D Carucci, D Zimmerman. “A non-immunogenic small peptide derived from human MHC II b chain induces protection against malaria.” Presented at the Woods Hole ImmunoParasitology Meeting. Woods Hole, MA, USA, April 2002.
Y Charoenvit, G Brice, D Carucci, N Goel, K Rosenthal, A Walker, M Whelan, D Winship, D Zimmerman. “A non-immunogenic small peptide analogue to human MHC II b chain induces protective responses to tumor and infectious challenges.” Presented at Experimental Biology 2002 (Late breaking poster presentation LB517). New Orleans, LA, USA, April 2002.
Y Wang, E Talor, D Zimmerman, N Rose. “A Th1 peptide conjugate decreases disease severity in the A/J mouse model of autoimmune myocarditis.” Presented at Experimental Biology. New Orleans, LA, USA, April 2002.
D Zimmerman. “Antigen specific approach for treatment of immune disorder.” Presented at the SMi Conference Immune Disorders. London, UK, March 2002.
N Goel, D Zimmerman, K Rosenthal. “A L.E.A.P.S.(TM) heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.” Presented at the ASM Conference on Immunity to Bacterial, Viral and Protozoal Pathogens. Savanah, GA, USA, March 2002.
G Taylor, L Ely, T Wolff, C Davis, O Ioffe, K Shah, E Talor, R Daniel, N Khanna. “Immunotherapy with Leukocyte Interleukin, Injection for human papilloma virus (HPV) induced cervical dysplasia in HIV patients.” 33rd SGO Conference. Miami, FL, March 2002
D Zimmerman. “Use of L.E.A.P.S.(TM) for disease.” Presented at the SMi Conference Anti-Inflammatory Therapeutics. London, UK, January 2002.
D Zimmerman, J Lloyd, D Heisey, M Winship, M Siwek, E Talor, P Sarin. “Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1SF -2-microglobulin or MHCß-p17) and peptide segments of human chain ß-II.” Vaccine 2001; 19:4750-4759.
G Taylor, L Ely, T Wolff, C Davis, O Ioffe, E Talor, N Khanna, E Tramont. “Immunotherapy with Leukocyte Interleukin, Injection for human papilloma virus (HPV) induced cervical dysplasia in HIV patients.” Presented at the 40th Annual ACOG (American College of Obstetricians and Gynecologists) Meeting of the Armed Forces District. Norfolk, VA, USA, October, 2001.
G Taylor, L Ely, T Wolff, C Davis, O Ioffe, E Talor, N Khanna, R Redfield, E Tramont. “Immunotherapy with Leukocyte Interleukin, Injection (Multikine®) for human papilloma virus (HPV) induced cervical dysplasia in HIV patients.” Presented at the Annual Meeting of the International Society for Interferon and Cytokine Research. Cleveland, OH, USA, October 2001.
o Click here to view Cleveland Abstract without pictures. POWERPOINT PRESENTATION
M Siwek, D Winship, M Manner, D Zimmerman. “C clade HGP-30 (p17 aa 86-115) based peptide conjugates as potential therapeutic and prophylactic HIV-1 vaccine antigens.” Presented at the AIDS Vaccine Conference. Philadelphia, PA, USA, September 2001.
V Pisarev, P Parajuli, R Mosley, J Sublet, L Kelsey, P Sarin, D Zimmerman, D Winship, J Talmadge. “FLT3 Ligand enhances the immunogenicity of gag based HIV-1 Vaccine.” Int J Immunopharmacol 2000; 22:865-876.
R Wang, F Baraceros, D Zimmerman, S Hoffman. “Protective immunity against malaria by immunization with PySSP2 CD4+ T helper epitope conjugated to MHC class II binding ligand, MHC-IIb -chain peptide 135-149.” Presented at the Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, USA, October 2000.
H Azzazy, T Izumikawa, P Cummings, D Zimmerman. “Immunogenicity of DNA vaccines encoding tuberculosis early secretory protein ESAT-6 fused to chemokines.” Presented at ICAAC. Toronto, Ontario, Canada, September 2000.
R Feinmesser, R Sadov, P Chretien, M Dudkiewicz. “Peritumoral injection of natural cytokine mixture induces tumor regression in head and neck cancer in patients in Phase I/II clinical trial.” Presented at the 5th International Conference on Head and Neck Cancer. San Francisco, CA, USA, August 2000.
H Mao, N Goel, Q Rong, D Zimmerman, J Lloyd, K Rosenthal. “Th1 or Th2 response to HSV peptide epitopes is determined by incorporation into L.E.A.P.S.(TM) heteroconjugates.” Presented at the 3rd Annual Conference on Vaccine Research. Washington, DC, USA, May 2000.
V Pisarev, P Parajuli, R Mosley, J Sublet, D Zimmerman, P Sarin, M Winship, J Talmadge. “Enhanced immunogenicity of an HIV gag peptide by conjugation to MHCIIb 2 epitopes is augmented, with type 1 T cell responses by flt3 ligand.” Presented at the AAI/CIS Annual Meeting. Seattle, WA, USA, May 2000.
V Pisarev, P Parajuli, L Kelsey, R Mosley, P Sarin, D Zimmerman, D Winship, J Talmadge. “FLT3 Ligand (FLT3L) and IL-1b Bioacative Fragment, T Cell Specific Adjuvants for Peptide Vaccines.” Presented at the FASEB Meeting. Washington, DC, USA, April 1999.
J Talmadge, P Sarin, D Zimmerman. “HGP30 p17 gag HIV Peptide Vaccine: Conjugation to IL1b (163-171) Fragment or Immunization Following Flt3 Ligand Co-Administration Increases T cell Specific Immune Responses.” Presented at the 14th Annual CIS Meeting. Washington, DC, USA, April 1999.
V Pisarev, P Parajuli, L Kelsey, R Mosley, P Sarin, D Zimmerman, M Winship, J Talmadge. “FLT3 ligand (Flt3L) and IL-1 bioactive fragment, T cell specific adjuvants for peptide vaccines.” Presented at Experimental Biology. Washington DC, USA, April 1999
K Rosenthal, H Mao, W Horne, C Wright, D Zimmerman. “Immunization with a L.E.A.P.S.(TM) Heteroconjugate containing a CTL epitope and a peptide from ß-2-microglobulin elicits a protective and DTH response to Herpes Simplex type 1.” Vaccine 1999; 17:535-542.
J Talmadge, V Pisarev, L Kelsey, M Winship, D Zimmerman, P Sarin. “Heteroconjugation to an IL-1b nonamer or the use of Flt3 ligand are potent adjuvants for T cell responses to HGP-30 peptide vaccine.” Presented at the Keystone Conference. Keystone, CO, USA, January 1999.
P Sarin, J Talmadge, P Heseltine, N Murcar, H Gendelman, R Coleman, L Kelsey, S Beckner, M Winship, J Kahn. “Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.” Vaccine 1999; 17:64-71.
K Rosenthal, H Mao, D Zimmermen. “Immunization with a L.E.A.P.S.(TM) heteroconjugate containing a CTL epitope and a peptide from ß-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1.” Presented at the 23rd International Herpes Virus Workshop. York, UK, August 1998.
P Sarin, J Lloyd, D Heisey, E Talor, M Winship, D Zimmerman. “HGP-30W vaccine induces cross clade recognition (A,B,C,D,E) and amplification of cellular immune responses (TH-1) with different adjuvants and in a prime-boost protocol.” Presented at the 12th World AIDS Conference. Geneva, Switzerland; June 1998.
D Zimmerman, J Ulrich, C Wright, J Lloyd, M Winship and P Sarin. “Cross clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.” AIDS Research and Human Retroviruses 1998; 14:741-749.
D Zimmerman. “L.E.A.P.S.(TM) : A new technology for selective antigen-specific immune responses.” Presented at New Technologies and Applications. Palm Beach, FL, USA, April 1998.
D Zimmerman. “L.E.A.P.S.(TM) : A new vaccine technology for infectious diseases, some results from HSV, HIV, and TB in mice.” Presented at the Conference for Antiinfectives Development. Brussels, Belgium, March 1998.
K Rosenthal, H Mao, W Horne, C Wright, D Zimmerman. “A heteroconjugate vaccine containing a T cell antigen peptide elicits a protective and DTH response to herpes simplex virus type 1.” Presented at the 37th ICAAC. Toronto, Ontario, Canada, September 1997.
D Zimmerman, J Lloyd, M Winship, P Sarin. “Modified HGP-30 incorporated into a peptide heterconjugate: A novel approach in HIV vaccine development.” Presented at the 4thRetrovirus Meeting. Washington DC, USA, January 1997.
D Zimmerman, S Morris, D Rouse, K Worthington, D Elliott, K Rosenthal. “Immunization with peptide heteroconjugates primes a TH1 associated antibody (IgG2a) response which recognizes the native epitope on the 38 kDa protein of mycobacterium tuberculosis.” Vacc. Res. 1996; 5:103-118.
D Zimmerman, K Bergmann, K Rosenthal, D Elliott. “A new approach to T cell activation: Natural and synthetic conjugates capable of activating T cells.” Vacc. Res. 1996; 5:91-102.
P Sarin, C Mora, P Naylor, R Markham, D Schwartz, J Kahn, P Heseltine, B Gazzard, M Youle, A Rios, A Goldstein. “HIV-1 p17 synthetic peptide vaccine HGP-30: Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.” Cellular and Molec. Biol. 1995; 41:401-407.
M Chirigos, E Talor, R Sidwell, R Burger, R Warren. “Leukocyte Interleukin, Injection (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.” Immunopharm. and Immunotox. 1995; 17(2): 247.
D Zimmerman, K Rosenthal, D Elliott. “The use of peptide heteroconjugates to prime TH1 or TH2 activity to an epitope of Mycobacterium tuberculosis.” Presented at the ICAAC. San Francisco, CA, USA, September 1995.
P Sarin, R Markham, D Schwartz, P Naylor, J Kahn, P Heseltine, B Gazzard, M Youle, A Rios, A Goldstein. “Cytotoxic and humoral immune responses to HIV-1 p17 synthetic peptide HGP-30 in human volunteers.” Vacc. Res. 1994; 3:49-57.
J Hadden, J Endicott, P Baekey, P Skipper, E Hadden. “Interleukins and contrasuppression induce immune regression of head and neck cancer.” Arch. Otolar. Head Neck Surg. 1994; 120: 395-403.
J Kahn, D Stites, J Scillian, N Murcar, R Stryker, P Volberding, P Naylor, A Goldstein, P Sarin, V Simmon, S Wang, P Heseltine. “A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects.” AIDS Res. Hum. Retroviruses 1992; 8:1321-1325.
J Jiang, F Chu, P Naylor, J Kirkley, J Mandeli, J Wallace, P Sarin, A Goldstein, J Holland, J Bekesi. “Presence of specific antibodies to synthetic epitopes of HIV-1 gag p17 correlates with stages of HIV-1 infection in homosexuals and IV drug abusers.” J. AIDS 1992; 5:382-390.
B Gazzard, M Youle, V MacDonald, C O’Toole, D Stambuk, A Rios, A Achour, D Zagury, P Naylor, P Sarin, A Goldstein. “Safety and immunogenicity of HGP-30: Evaluation of a synthetic HIV-1 p17 vaccine in healthy HIV seronegative volunteers.” Vacc. Res. 1992; 1:129-135.
P Naylor, M Sztein, S Wada, S Maurer, D Hilterman, J Kirkley, C Naylor, B Zook, R Hitzelberg, C Gibbs, D Zagury, A Achour, C O’Toole, B Gazzard, M Youle, A Rios, P Sarin, A Goldstein. “Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17 based synthetic peptide AIDS vaccine HGP-30/KLH.” Int. J. Immunopharm. 1991; 13(suppl. 1):117-127.
P Naylor, A Heithaus, A Kale, R Erdos, J Kirkley, A Goldstein. “Diagnostic assays for human immunodeficiency virus infection and for clinical progression by use of synthetic p17 peptide epitopes.” Monogr. Virol. 1990; 18:74-90.
A Achour, D Picard, D Zagury, P Sarin, R Gallo, P Naylor, A Goldstein. “HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17 is a target for cytotoxic lymphocytes in HIV infected individuals.” Proc. Natl. Acad. Sci. U.S.A. 1990; 87:7045-7049.
E Fagan, M Pulley, A Limb, R Wolstencroft, C Cranenburgh, C De Vinci, J Karani, M Michell, H Nunnerley, S Zaman, G Pizza, D Dumonde, R Williams. “Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma.” Canc. Treatm. Rev. 1989; (Supp. A):151-160.
M Pulley, V Nagendran, J Edwards, D Dumonde. “Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.” Lymph. Res. 1986; 5(supp. 1).
